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Knowledge Transfer Statement 
Brain activity related to activation of the autonomic nervous system in chronic fatigue syndrome 
patients who screened positive for painful temporomandibular disorder was greater than in patients 
who screened negatively; activity was seen in brain regions associated with autonomic functions and 
pain. These findings suggest that autonomic dysfunction may play a role in the pathophysiology of 
both conditions, explain some of the apparent co-morbidity between the two, and offer avenues to 
help with treatment. 
 
 
 
Abstract 
INTRODUCTION: Dysfunction of the autonomic nervous system (ANS) is seen in chronic fatigue 
syndrome (CFS) and temporomandibular disorders (TMD). Both conditions have poorly understood 
pathophysiology. Several brain structures which play a role in pain and fatigue, such as the insular 
cortex and basal ganglia, are also implicated in autonomic function. 
OBJECTIVES: ANS dysfunction may point to common neuro-physiological mechanisms underlying 
the predominant symptoms for both CFS and TMD. No studies to date have investigated the 
combination of both conditions. Thus our aim was to test whether CFS patients with or without TMD 
show differences in brain responses to autonomic challenges.  
METHODS: In this exploratory functional imaging study, CFS patients who screened positive for 
TMD (n=26), patients who screened negative for TMD (n=16) and age-matched control participants 
(n=10) performed the Valsalva manoeuvre whilst in a 3T MRI scanner. This manoeuvre is known to 
activate the ANS. 
RESULTS: For all three groups, whole-brain F-test showed increased brain activation during the 
manoeuvre in superior and inferior frontal gyri, left and right putamen and thalamus, and insular 
cortex. Furthermore, group contrasts with small-volume correction showed that CFS patients who 
screened positive for TMD showed greater activity in the left insular cortex compared to patients who 
screened negative, and in the left caudate nucleus compared to controls. 
CONCLUSION: Our results suggest that increased activity in cortical and subcortical regions 
observed during autonomic challenges may be modulated by fatigue and pain. ANS dysfunction may 
be a contributing factor to these findings and further work is required to tease apart the complex 
relationship between CFS, TMD and autonomic functions. 
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Introduction 
The pathophysiology of chronic fatigue syndrome (CFS) remains poorly understood. In practice, it is 
clinically characterised by debilitating fatigue lasting at least six months, alongside a host of co-
occurring symptoms such as poor sleep, post-exertional malaise, muscle and joint pain, and reduced 
cognitive capacity. The gold standard diagnostic criteria allow for any combination of at least four 
out of eight symptoms (Fukuda et al. 1994); consequently, there are many possible permutations. 
The resulting symptom clusters alongside the predominant symptom of pain and fatigue may reflect 
different CFS phenotypes, for example, due to other co-morbid conditions. The different phenotypes 
may have different underlying pathogenesis, which may increase the difficulty of finding appropriate 
treatments. 
Despite the potential heterogeneity of CFS, nearly 90% of patients with CFS have associated 
autonomic nervous system (ANS) dysfunction (Newton et al. 2007; Robinson et al. 2015; Van 
Cauwenbergh et al. 2014). The ANS may contribute to common neuro-physiological mechanisms 
underlying some of the diagnostic symptoms of CFS, particularly pain and fatigue (Newton et al. 
2007). Thus the aim of our exploratory study is to test whether there are differences in brain 
responses to autonomic challenges between two possible CFS phenotypes – patients who also 
screen positive for painful Temporomandibular Disorders (TMD) and patients who screen negative 
for TMD. Other clinical pain conditions in the absence of CFS, such as migraines or fibromyalgia, 
may also be associated with ANS dysfunction (Borsook et al. 2016; Martinez-Martinez et al. 2014). 
Based on our previous studies (Finkelmeyer et al. 2018a; Finkelmeyer et al. 2018b; Robinson 
et al. 2015), we focused on TMD in the current brain imaging study for several reasons. First, 
differences in TMD patients’ heart rate variability compared to controls during rest and orthostatic 
challenge have been observed, which correlated with the degree of pain sensitivity (Chinthakanan 
et al. 2018; Maixner et al. 2011). Heart rate variability can be an indicator of autonomic dysfunction 
(Robinson et al. 2015). Second, increased resting heart rate variability increased the likelihood of 
TMD in a large prospective cohort study (Greenspan et al. 2013). Third, there is a higher prevalence 
of TMD in patients with CFS, and vice versa, than the reported population prevalence (Johnston et 
al. 2013; Robinson et al. 2016; Slade et al. 2013). Lastly, ANS dysfunction is greater in CFS patients 
who screened positive for TMD compared to those who screened negative for TMD (Robinson et al. 
2015). It is possible therefore that the presence of TMD in CFS indicates a potential phenotype with 
a greater burden on the ANS. 
Centrally both cortical and subcortical structures are involved in autonomic functions, 
including the insular cortex (Macey et al. 2012; Seifert et al. 2013) and basal ganglia (Miller et al. 
2014; Pazo and Belforte 2002). Structures within the basal ganglia also have a role in fatigue (Miller 
et al. 2014), and the insular cortex is part of a network of cortical regions involved in pain processing  
(Brugger et al. 2012; Harte et al. 2016; Seifert et al. 2013). The insular cortex is particularly 
interesting because imaging studies with CFS and TMD patients show anatomical and functional 
differences between each patient group and control groups in this region (Finkelmeyer et al. 2018b; 
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Miller et al. 2014; Younger et al. 2010). Thus given their potential role in both autonomic functions 
and pain processing, we hypothesise that brain responses to autonomic challenges in the insular 
cortex and basal ganglia may be modulated by the presence of CFS and TMD. 
Building on our previous work with the same cohort of patients (Finkelmeyer et al. 2018a; 
Finkelmeyer et al. 2018b; Robinson et al. 2015), we used functional magnetic resonance imaging 
(fMRI) to measure whether different CFS phenotypes (i.e., presence or absence of TMD) show 
functional brain differences related to autonomic functions. This is an important aim because not all 
studies find a link between CFS and ANS dysfunctions (Robinson et al. 2015; Timmers et al. 2002). 
Similarly, there are discrepancies in whether researchers find cerebral anatomical differences 
between individuals with and without CFS (Finkelmeyer et al. 2018b; Puri et al. 2012; van der Schaaf 
et al. 2017). The different findings reported in previous studies may be a consequence of diverse 
CFS symptom clusters or failure to control for other co-morbidities. Thus in the current study, we 
compared brain activation in response to an autonomic respiratory challenge (Valsalva manoeuvre) 
between CFS patients who screened positive or negative for TMD. This manoeuvre is used clinically 
to induce changes in systemic blood pressure and heart rate. Given our hypothesis, we expect blood 
oxygenation-level dependent (BOLD) responses to differ between the two CFS groups during this 
manoeuvre, and between the patient groups and the control group. We further expect to observe 
these differences in insular cortex (Brugger et al. 2012; Finkelmeyer et al. 2018a; Harte et al. 2016), 
although other brain regions that are involved in autonomic function or pain processing may also 
show differences (Seifert et al. 2013). 
 
Methods 
Participants 
A total of 52 participants were tested in the current study, which included the same cohort groups 
from our previous studies (Finkelmeyer et al. 2018a; Finkelmeyer et al. 2018b; Robinson et al. 2015). 
Table 1 provides a breakdown of participant information per group. CFS patients were recruited via 
the Newcastle and North Tyneside National Health Service Clinical CFS Service as part of a larger 
project investigating the role of autonomic dysfunctions in CFS. They were included if they fulfilled 
the Fukuda diagnostic criteria for CFS (Fukuda et al. 1994) and screened negative for current or 
past major depressive episodes, as assessed by a trained medic using the Structured Clinical 
Interview for the Diagnostic and Statistical Manual for Mental Disorders (version IV; SCID-IV (First 
et al. 2002)). We used a TMD screening instrument (Gonzalez et al. 2011) to screen for TMD. This 
instrument is a 6-item self-report questionnaire and has very high sensitivity and specificity for painful 
TMD (>95%). Patients filled out the DePaul Symptom Questionnaire (DSQ; (Jason et al. 2010)), the 
Fatigue Impact Scale (FIS; (Fisk et al. 1994)), and the Pain Catastrophizing Questionnaire (PCQ; 
(Sullivan et al. 1995)). Age-matched participants for the control group were recruited as part of the 
same larger project; they had no diagnoses of CFS, screened negative for TMD, and no history of 
major psychiatric and physical health conditions. Participants underwent a medical assessment at 
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the time of recruitment that identified that they did not have other diagnoses. Thus there were three 
groups: CFS patients who screen positive for TMD (screener score3), CFS patients who screen 
negative for TMD (screener score2), and age-matched participants without CFS diagnoses and 
screen negative for TMD (screener score=0). These will be referred to as the CFS+, CFS- and 
Control group, respectively. All participants provided written informed consent. The study was 
conducted in accordance with the Declaration of Helsinki. The study was reviewed and approved by 
the local NHS Research Ethics Committee (REC 12/NE/0146, CLRN ID 97805). 
 
--- Insert Table 1 about here --- 
 
Image acquisition during the Valsalva manoeuvre 
A T1-weighted anatomical scan was collected for each participant using a 3D MPRAGE sequence 
(TE = 4.6 ms; TR = 8.3 ms; flip angle = 8°; three-dimensional acquisition field of view (FOV) = 240 
mm (AP) x 216 mm (FH) x 180 mm (LR); 1 mm isotropic voxel size). These scans were processed 
and analysed in our previous study (Finkelmeyer et al. 2018b), so are not reported further. 
In the same scanning session, functional (T2*) echo planar images (EPI) were acquired in a 
single functional run while participants performed four Valsalva manoeuvres. Figure 1 (panel A) 
illustrates the time course of the functional scan and the periods of interest for our analyses. The 
time course consisted of a 4-s preparation period (light grey region), a 16-s Valsalva period and a 
40-s rest period, repeated four times. The rest period was divided into a 20-sec post-Valsalva period 
for the purpose of analyses (dark grey region; see Figure 1, panel A). We followed our previous 
protocol for MRI acquisition during the Valsalva manoeuvre (Bohr et al. 2015). Participants were 
guided through the protocol using a projection screen. First, they were presented with visual 
instructions to inhale before the manoeuvre during the preparation period, and then to start and stop 
exhaling during the Valsalva period. During the Valsalva period, participants maintained an 
expiratory pressure of 40 mmHg against a closed outlet which provided a resistance so that their 
expiratory pressure could be measured using an in-house device and software. Participants received 
visual feedback (a bar chart) of the measured expiratory pressure to help them maintain this target 
pressure. All participants in this study were able to maintain the target pressure. Figure 1 (panel B) 
illustrates CFS+ patient’s exhaled pressure trace. Participants were scanned in a 3 Tesla Philips 
Intera Achieva scanner using an eight-channel head coil. We used a customised dual gradient echo 
sequence to acquire 135 images (repetition time [TR] = 2000 ms, 270 sec total data acquisition; 
echo times [TE1/TE2] = 13.82/39.27 ms; flip angle = 90°; two-dimensional acquisition FOV = 240 
mm x 240 mm; matrix size = 112 pixels x 112 pixels; and 20 slices of 4-mm thickness). 
 
--- Insert Figure 1 about here --- 
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fMRI pre-processing 
The functional images (135 images) were realigned to the mean of all functional images and directly 
normalised to a standard Montreal Neurological Institute (MNI) T2∗-weighted template with a 
resampled voxel size of 3 mm x 3 mm x 3 mm. The normalised images were spatially smoothed with 
a 6 mm at full-width-half-maximum Gaussian kernel to improve the signal-to-noise ratio and to allow 
for comparisons across participants. We then applied a high-pass filter with a cut-off of 128 s to 
remove low-frequency drifts in the signal, and used an autoregressive model to estimate serial 
correlations in the data and adjust degrees of freedom accordingly. 
 
fMRI whole brain analyses 
The pre-processed data were analysed using SPM12 (Friston et al. 1994). We used the general 
linear model (GLM) with a two-step mixed-effects approach. First, a fixed-effects model was used to 
analyse each participant’s data set. Second, a random-effects model was used to analyse the 
individual datasets at the group level. No additional smoothing of the images was used at the group 
level. 
 At the subject level, we first created a design matrix for each participant as follows. The 
preparation, Valsalva and post-Valsalva periods were each modelled as box-car time series and 
convolved with a canonical hemodynamic response function. The remaining time points were 
unmodelled and served as an implicit baseline. The global signal (i.e., the mean time series 
computed over all grey-matter voxels and the six movement parameters from the realignment were 
included as regressors of no interest in the matrix. We then fitted a linear combination of the 
regressors to the functional data to estimate beta weights for each period and create a corresponding 
beta image. Lastly, we calculated a contrast image between the Valsalva and the other two periods 
from their corresponding beta images (i.e., Valsalva – [preparation + post-Valsalva]). The resulting 
value at each voxel in the contrast image reflects the magnitude of brain activation during the 
Valsalva manoeuvre at that voxel. 
 At the group level, we conducted a series of analyses to compare contrast images between 
the CFS+, CFS- and Control groups. First, we conducted an F-test to localize clusters in which any 
of the three groups showed beta weights significantly greater than zero. For this test, we used an 
initial (uncorrected) threshold of p < 0.0001 and a minimum cluster size of k = 100 voxels. Second, 
we conducted whole-brain pairwise t-tests between groups using an initial (uncorrected) threshold 
of p < 0.01 and a minimum cluster size of k = 10 voxels. Based on our hypotheses that insular cortex 
and basal ganglia may be involved in autonomic functions, pain and fatigue, we used significant 
clusters from the F-test which overlapped with these anatomical regions as separate masks for post-
hoc small volume correction (SVC) to increase statistical power for our group comparisons. Lastly, 
we report clusters which had p (uncorrected) < 0.05 at the cluster level. We do not consider these 
uncorrected clusters as significant and only present them for exploratory purposes. 
 
7 
 
Results 
Brain regions showing consistent increased activation across groups 
Figure 2 and Table 2 show the significant clusters from the F-test. There is increased brain activation 
in several cortical and subcortical regions when participants performed the Valsalva manoeuvre 
(Figure 2, panel A). The cortical clusters included those in superior and inferior frontal gyri. The 
subcortical clusters were centred within left and right putamen and thalamus. Part of the putamen 
clusters overlapped with insular cortex (Figure 2, panel B; left hemisphere: 59 voxels, 16.0%; right 
hemisphere: 23 voxels, 7.5%; based on the WFU PickAtlas; 
http://fmri.wfubmc.edu/software/PickAtlas, version 2.4; (Maldjian et al. 2003)). 
 
--- Insert Figure 2 about here --- 
 
--- Insert Table 2 about here --- 
 
Brain regions showing differences between CFS patients who screened positive or negative for TMD 
Figure 3 and Table 2 show the clusters from whole-brain pairwise t-tests between the CFS+ and 
CFS- group. These comparisons tested whether the presence of TMD in CFS patients affected brain 
activity during the Valsalva manoeuvre. Only the left cluster from the F-test centred on the putamen 
overlapped with the uncorrected clusters from this contrast. After small volume correction with this 
cluster, there was one cluster within left insular cortex which showed significantly larger BOLD 
responses for the CFS+ group compared to the CFS- group. To facilitate future studies, we computed 
the effect size of this group difference as follows. For each participant in each group we first 
calculated the mean beta value for the cluster (i.e., we averaged across the 26 voxels in the cluster 
from the contrast image: Valsalva – [preparation + post-Valsalva]), and then we calculated Hedges’ 
g (for unequal group sample sizes) as our measure of effect size. For the CFS+ group, the mean 
beta value averaged across participants was 0.70 (arbitrary units), with a standard deviation of 0.51. 
For the CFS- group, the mean beta value was 0.13, with a standard deviation of 0.41. We found a 
large effect size (Hedges’ g = 1.27; 95% confidence interval: CFS+ [0.43 0.97], CFS- [-0.03 0.30]). 
We did not find any significant clusters for the opposite contrast: there were no clusters showing 
larger responses for the CFS- compared to the CFS+ group. 
 
--- Insert Figure 3 about here --- 
 
Brain regions showing differences between CFS patients and age-matched participants 
Next we compared each patient group to the Control group using whole-brain pairwise t-tests. For 
the comparison between the CFS+ and Control groups, there was one cluster within left caudate 
showing significantly larger BOLD responses for patients than controls (after small volume 
correction). The caudate is part of the basal ganglia, which is involved in autonomic functions (Miller 
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et al. 2014; Pazo and Belforte 2002) and may play a role in fatigue (Miller et al. 2014). For the CFS+ 
group, the mean beta value averaged across participants was 0.94, with a standard deviation of 
0.65. For the Control group, the mean beta value was -0.33, with a standard deviation of 0.84. We 
found a large effect size also for this cluster (Hedges’ g = 1.75; 95% confidence interval: CFS+ [0.60 
1.29], Control [-0.93 0.27]). There were no significant clusters within insular cortex for the comparison 
between the CFS- and Control group, although there were clusters in other cortical regions for this 
comparison (p < 0.05, uncorrected at the cluster level). These include clusters in the cingulate cortex, 
which is a region that also plays a role in pain processing (Boccard et al. 2014; Schmidt-Wilcke et 
al. 2014). Finally, there were no significant clusters in which BOLD responses were significantly 
larger for the Control group compared to either patient groups. 
 
Discussion 
In the current fMRI study, brain activity was measured whilst patients and healthy participants 
performed the Valsalva manoeuvre to cause autonomic activation. Brain activity was compared 
between three groups: CFS patients who screened positive for TMD; those who screened negative 
for TMD; and age-matched participants who did not have a CFS diagnosis and screened negative 
for TMD (i.e., a control group). None of the participants had any current or previous major depressive 
episodes, or other major medical conditions. Consistent with previous work (Henderson et al. 2002; 
Macey et al. 2012), there was increased brain activity during the Valsalva manoeuvre across all three 
groups within left and right putamen with voxels overlapping insular cortex (Figure 2, panel B; Table 
2). There was also increased brain activity in the thalamus and frontal lobe. In addition, CFS patients 
who screened positive for TMD showed: (1) increased brain activity during the Valsalva manoeuvre 
in a cluster within left insular cortex relative to CFS patients who screened negative for TMD; and 
(2) increased brain activity in left caudate relative to healthy controls (Table 2). By comparison, there 
were some preliminary evidence that CFS patients who screened negative for TMD showed 
increased brain activity only in temporal and frontal cortices during the Valsalva manoeuvre relative 
to controls. The functional differences between groups reported here complement differences in grey 
matter volume previously reported for the same patient cohorts (Finkelmeyer et al. 2018b). In that 
study, CFS patients showed increased grey matter volume in insula, temporal and frontal gyri, and 
thalamus relative to healthy controls. 
The insular cortex has a known role in pain processing (Harte et al. 2016; Seifert et al. 2013), 
and—together with the limbic system—form part of the higher brain functioning pathway for 
ascending orofacial nociception beginning in the Trigeminal peripheral first order afferents. The 
results from the current study suggest that the increase in insula activity in response to the Valsalva 
manoeuvre may be amplified by the additional orofacial pain in CFS patients who screened positive 
for TMD compared to those who screened negative for TMD. That is, the Valsalva manoeuvre 
engages the autonomic system resulting in insula activity (across all groups). This activity is amplified 
in CFS+ patients by the additional orofacial pain they experience. The difference between the two 
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patient groups was found only in the left insula. This hemispheric asymmetry may be related to the 
finding that insula responses to the Valsalva manoeuvre in healthy participants is larger in the left 
compared to the right hemisphere (Macey et al. 2012), which may allow for more differential changes 
between the two patient groups to be detected. 
 Previous functional imaging studies have shown increased brain activity in insular cortex 
during the Valsalva manoeuvre in healthy cohorts, consistent with this region’s role in autonomic 
functions (Henderson et al. 2002; Macey et al. 2012). Although we hypothesised that ANS 
dysfunction may contribute to CFS (Newton et al. 2007; Robinson et al. 2015; Van Cauwenbergh et 
al. 2014), we only found a significant difference in left caudate between CFS patients who screened 
positive for TMD and control participants. The caudate is part of the basal ganglia, which may be 
involved in autonomic functions and fatigue (Miller et al. 2014; Pazo and Belforte 2002). The 
combination of CFS and TMD may increase the burden on the ANS for these patients, leading to the 
observed functional difference in the caudate nucleus. We did not find significant differences in brain 
activity in insula between either of the CFS patient group and the control group. We do not know 
why this was the case, although the combination of the small number of controls and unequal sex 
distribution across the three groups may be contributing factors. There were some preliminary 
functional differences in other cortical structures between CFS patients who screened negative for 
TMD and control participants (Table 2). 
The Valsalva manoeuvre elicits both sympathetic and parasympathetic responses (Macey et 
al. 2012). The findings from the current study cannot pinpoint which system (or both) may be driving 
the functional differences observed between our participant groups. That said, an earlier study with 
the same patient cohort found that CFS patients with TMD (screened positive) showed evidence of 
greater dominance of the parasympathetic nervous system relative to control (Robinson et al. 2015). 
By comparison, CFS patients without TMD (screened negative) showed no differences to control on 
heart rate variability measures related to both of these systems. These findings reflect dysfunction 
of the sympathetic nervous system, with increased parasympathetic activity compensating for 
chronic elevated levels of sympathetic activity (Robinson et al. 2015). Related to this, studies of heart 
rate variability in patients with only TMD found similar elevated level of sympathetic activity 
(Chinthakanan et al. 2018; Maixner et al. 2011). Future studies with CFS patients could use other 
autonomic challenges such as the hand grip challenge, which is a non-painful sympathetic challenge, 
to further refine our understanding of the role of the insular cortex in CFS. It is worth noting that the 
Valsalva manoeuvre activates body receptors in the somatosensory pathway which may be affected 
by pain conditions; thus the results reported may relate to differences in somatosensory sensitivity 
rather than autonomic activity per se (Khurana 2014). Future studies are required to tease apart 
autonomic and somatosensory activity (e.g., using somatosensory amplification scale as a co-variate 
measure (Koteles and Witthoft 2017)). 
Taking into consideration the results across the studies with the same participant cohort 
(Finkelmeyer et al. 2018a; Finkelmeyer et al. 2018b; Robinson et al. 2015), we have identified 
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several measures from heart rate variability to anatomical and functional measurements that 
discriminate between potential CFS phenotypes; in our case, CFS patients who screen positive or 
negative for TMD. These measures in combination point to the importance of autonomic functions 
for moderating fatigue and pain—two diagnostic symptoms of CFS. Thus, treatments which 
modulate these functions may help patients manage their symptoms more effectively. For example, 
beta-blockers may be an effective pharmacological intervention (Light et al. 2009). Psychosocial 
interventions may also be effective; for example, diaphragmatic breathing exercises may help 
harness the innate, inbuilt functionality of the Vagus nerve to increase parasympathetic activity to 
help CFS patients with and without co-morbid TMD cope with persistent pain (Bordoni et al. 2016). 
If there is no intervention, a negative feedback loop may develop as more persistent pain will 
increase negative affect and reinforce ANS dysfunction which will subsequently worsen pain 
experience. 
There are a number of limitations in the current study. First, we must bear in mind differences in 
sample size across the three groups in the current study, particularly the small number of controls. 
There was also a different ratio of females to males in each group. Second, we did not know the 
participants’ pain state while they were being scanned (or any painful episodes they may have 
experienced on the day of the scan). However, CFS patients who screened positive for TMD have 
higher self-reported pain experiences (as measured by the pain-related questions from the DSQ 
scores) compared to patients who screened negative for TMD (Table 1). That said, these limitations 
may contribute to the non-significant functional differences between groups. Third, our patient 
recruitment and screening excluded those with other medical conditions that share symptoms with 
CFS, such as migraines and fibromyalgia, which may also be the result of ANS dysfunction (Borsook 
et al. 2016; Light et al. 2009; Martinez-Martinez et al. 2014; Schmidt-Wilcke et al. 2014). Similar to 
CFS, fibromyalgia, in particular, affects predominantly females and leads to fatigue and pain 
symptoms. Lastly, we did not confirm our TMD screening with clinical examination so it is likely that 
there was a heterogeneous sample in terms of painful TMD; we therefore do not know whether the 
orofacial pain was of a muscular or arthrogenous origin, and whether it was acute or chronic in onset 
and duration. 
 
Conclusion 
In the current study, functional differences in cortical and subcortical regions between CFS patient 
groups and between patient and control groups were found during ANS activation. Although there 
were limitations in our exploratory study, it is the first study to scan a relatively large number of CFS 
patients, while controlling for additional pain conditions and depression. Given our promising results, 
future work can use similar fMRI paradigms to systematically compare and contrast brain responses 
to parasympathetic and sympathetic autonomic challenges across different clinically-diagnosed 
patient groups that share pain and fatigue as major symptoms. 
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Figure Captions 
 
Figure 1. (A) The Valsalva-manoeuvre protocol used in the current study. During the manoeuvre, 
participants was provided with visual feedback to maintain an expiratory pressure of 40 mmHg 
against a closed outlet. The protocol consisted of a 4-s preparation period, a 16-s Valsalva period 
and a 40-s rest period, repeated 4 times. The rest period was divided into a 20-sec post-Valsalva 
period for the purpose of analyses. (B). An example of an exhalation trace from a CFS+ patient 
during the entire functional run. 
 
Figure 2. (A) Significant clusters from the F-test (all clusters: pFWE < 0.05). Cross hair at the cluster 
in right putamen (MNI coordinates: x = 33, y = -13, z = -5). (B) The axial slice (the same slice as in 
Panel A) illustrates the overlap (yellow) between anatomically defined left and right insular cortex 
(red) and the largest left and right clusters from the F-test (cyan). 
 
Figure 3. Uncorrected clusters in the left hemisphere from the comparison between the CFS+ and 
CFS- groups. Cross hair at the cluster in left insular cortex (MNI coordinates: x = -27, y = 14, z = 7; 
p = 0.037, significant after small volume correction). 
 
  
17 
 
Table 1. Participant information for each cohort group. 
 
Group 
Females/ 
Males 
Mean 
age* 
in years 
[min max] 
Mean 
Symptom 
Duration* 
in years 
(SD) 
Median 
TMD 
screener 
score 
[min max] 
Mean 
DSQ** 
(SD) 
Mean 
FIS** 
(SD) 
Mean 
PCQ* 
(SD) 
CFS+ 15/1 
43.9 
[26 54] 
12.1 
(10.4) 
4.5 
[3 7] 
39.6 
(28.6) 
104.6 
(37.1) 
13.8 
(10.8) 
CFS- 17/9 
46.7 
[23 68] 
15.1 
(10.2) 
0.0 
[0 2] 
18.8 
(14.1) 
83.6 
(29.8) 
10.2 
(9.9) 
Control 7/3 
49.4 
[25 65] 
N/A 0.0 2.7 (3.8) N/A N/A 
DSQ = pain-related items from the DePaul Symptom Questionnaire (Jason et al. 2010)(n=41); FIS = Fatigue Impact Scale (Fisk et al. 
1994)(n=41); PCQ = Pain Catastrophizing Questionnaire (Sullivan et al. 1995)(n=32); note that questionnaire data were not available 
for all patients 
*CFS+ did not differ from CFS- in age, symptom duration or PCQ scores, all ps > .34 
**CFS+ differed from CFS- in DSQ scores; t(39) = 3.11, p = 0.004; and marginally for FIS scores; t(39) = 2.01, p = 0.051 
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Table 2. The brain structures and statistics for clusters from the whole-brain analyses. The cluster 
size is the number of contiguous voxels in that cluster. The cluster p (unc) is the uncorrected p-value 
at the cluster-level. The peak p (unc) is the uncorrected p-value of the voxel with the largest activation 
in that cluster, and the peak MNI coordinates refer to that voxel’s position. For the F-test, all clusters 
were significant after whole-brain family-wise-error correction at the cluster-level (pFWE < 0.05). The 
values in parentheses refer to voxels that overlapped with anatomically defined insular cortex. For 
the different group comparisons, clusters with uncorrected p < 0.05 at the cluster-level are also 
reported for exploratory purposes. Two of the clusters were significant after small volume correction 
(SVC, reported in parentheses). 
 
 Peak MNI coordinates 
Structure Hemisphere 
cluster size 
(voxels) 
cluster p 
(unc) 
peak p 
(unc) 
x y z 
F-test 
Putamen 
(Insula) 
Right 
305 
(23) 
<.001 <.001 33 -13 -5 
Putamen 
(Insula) 
Left 
369 
(59) 
<.001 <.001 -30 -4 -2 
Thalamus Bilateral 773 <.001 <.001 3 -25 4 
Superior 
Frontal Gyrus 
Right 209 <.001 <.001 9 53 1 
Superior 
Frontal Gyrus 
Left 237 <.001 <.001 -9 47 -8 
Inferior Frontal 
Gyrus 
Left 115 <.001 <.001 -51 14 4 
CFS+ vs CFS- 
Insular Cortex Left 26 .108 
<.001 
(.037SVC) 
-27 14 7 
CFS+ vs Control 
Caudate Left 49 .034 <.001 
(.016SVC) 
-12 5 1 
CFS- vs Control 
Cingulate 
Gyrus 
Right 63 .018 <.001 18 -31 34 
Parietal Lobe Right 63 .018 <.001 27 -76 37 
Cuneus Left 56 .024 <.001 -15 -88 4 
Temporal Lobe Right 77 .010 <.001 33 -37 13 
Cingulate 
Gyrus 
Right 44 .042 .<001 9 -46 25 
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Figure 1. (A) The Valsalva-manoeuvre protocol used in the current study. During the manoeuvre, 
participants was provided with visual feedback to maintain an expiratory pressure of 40 mmHg 
against a closed outlet. The protocol consisted of a 4-s preparation period, a 16-s Valsalva period 
and a 40-s rest period, repeated 4 times. The rest period was divided into a 20-sec post-Valsalva 
period for the purpose of analyses. (B). An example of an exhalation trace from a CFS+ patient 
during the entire functional run. 
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Figure 2. (A) Significant clusters from the F-test (all clusters: pFWE < 0.05). Cross hair at the cluster 
in right putamen (MNI coordinates: x = 33, y = -13, z = -5). (B) The axial slice (the same slice as in 
Panel A) illustrates the overlap (yellow) between anatomically defined left and right insular cortex 
(red) and the largest left and right clusters from the F-test (cyan). 
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Figure 3. Uncorrected clusters in the left hemisphere from the comparison between the CFS+ and 
CFS- groups. Cross hair at the cluster in left insular cortex (MNI coordinates: x = -27, y = 14, z = 7; 
p = 0.037, significant after small volume correction). 
 
